Previous studies have shown that clusterin exerts protective effects in AD, including markedly improving Aβ clearance by binding to Aβ across the blood-brain barrier (BBB) [15], preventing Aβ aggregation [16, 17], and promoting lysosomes Aβ degradation [15, 18], which suggest clusterin was considered as a protector in AD. Here, CLU is linked to Alzheimer disease.